Related Experiment Video
Updated: Jun 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiviral Information Management System (AIMS): a prototype for operational innovation in drug development
Pravin R Jadhav1, Lauren Neal, Jeff Florian
1Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Pravin.Jadhav@fda.hhs.gov
Abstract:
This article presents a prototype for an operational innovation in knowledge management (KM). These operational innovations are geared toward managing knowledge efficiently and accessing all available information by embracing advances in bioinformatics and allied fields. The specific components of the proposed KM system are (1) a database to archive hepatitis C virus (HCV) treatment data in a structured format and retrieve information in a query-capable manner and (2) an automated analysis tool to inform trial design elements for HCV drug development. The proposed framework is intended to benefit drug development by increasing efficiency of dose selection and improving the consistency of advice from US Food and Drug Administration (FDA). It is also hoped that the framework will encourage collaboration among FDA, industry, and academic scientists to guide the HCV drug development process using model-based quantitative analysis techniques.
Related Concept Videos
Antiviral Nucleoside Inhibitors
In Vitro Drug Release Testing: Overview, Development and Validation
Automated Microbial Diagnostics
Inhibitors of Viral Protein Synthesis
Drug Discovery: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

